Do Bisphosphonates Reduce the Risk of Osteoporotic Fractures? An Evaluation of the Evidence to Date

Overview

Journal CMAJ

Date 2002 Jun 11

PMID 12054412

Citations 19

Authors

Anthony B Hodsman

David A Hanley

Robert Josse

Affiliations

Soon will be listed here.

Citing Articles

Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

Wells G, Hsieh S, Peterson J, Zheng C, Kelly S, Shea B Cochrane Database Syst Rev. 2025; 1:CD001155.

PMID: 39868546 PMC: 11770842. DOI: 10.1002/14651858.CD001155.pub3.

Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

Wells G, Hsieh S, Peterson J, Zheng C, Kelly S, Shea B Cochrane Database Syst Rev. 2024; 4:CD003376.

PMID: 38591743 PMC: 11003221. DOI: 10.1002/14651858.CD003376.pub4.

Trends in incidence of recorded diagnosis of osteoporosis, osteopenia, and fragility fractures in people aged 50 years and above: retrospective cohort study using UK primary care data.

Avgerinou C, Petersen I, Clegg A, West R, Osborn D, Walters K Osteoporos Int. 2023; 34(8):1411-1427.

PMID: 37162537 PMC: 10382342. DOI: 10.1007/s00198-023-06739-1.

Zoledronic Acid Does Not Retard Bone Union: A Randomized Controlled Trial in Fragility Intertrochanteric Femur Fractures.

Gulia A, Das S, Sondur S, Rajendran P, Mohanty A, Prakash V Cureus. 2023; 15(1):e33948.

PMID: 36819363 PMC: 9937685. DOI: 10.7759/cureus.33948.

Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

Wells G, Hsieh S, Zheng C, Peterson J, Tugwell P, Liu W Cochrane Database Syst Rev. 2022; 5:CD004523.

PMID: 35502787 PMC: 9062986. DOI: 10.1002/14651858.CD004523.pub4.

References

Nevitt M, Thompson D, Black D, Rubin S, Ensrud K, Yates A . Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med. 2000; 160(1):77-85. DOI: 10.1001/archinte.160.1.77. View

Harris S, Watts N, Genant H, McKeever C, Hangartner T, Keller M . Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282(14):1344-52. DOI: 10.1001/jama.282.14.1344. View

Ensrud K, Thompson D, Cauley J, Nevitt M, Kado D, Hochberg M . Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. J Am Geriatr Soc. 2000; 48(3):241-9. DOI: 10.1111/j.1532-5415.2000.tb02641.x. View

Schnitzer T, Bone H, Crepaldi G, Adami S, McClung M, Kiel D . Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano). 2000; 12(1):1-12. View

Klotzbuecher C, Ross P, Landsman P, Abbott 3rd T, Berger M . Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000; 15(4):721-39. DOI: 10.1359/jbmr.2000.15.4.721. View

Gillespie W, Henry D, OConnell D, Robertson J . Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev. 2000; (2):CD000227. DOI: 10.1002/14651858.CD000227. View

Cauley J, Thompson D, Ensrud K, Scott J, Black D . Risk of mortality following clinical fractures. Osteoporos Int. 2000; 11(7):556-61. DOI: 10.1007/s001980070075. View

Crilly R, Sebaldt R, Hodsman A, Adachi J, Brown J, Goldsmith C . Predicting subsequent bone density response to intermittent cyclical therapy with etidronate from initial density response in patients with osteoporosis. Osteoporos Int. 2000; 11(7):607-14. DOI: 10.1007/s001980070082. View

McClung M, Geusens P, Miller P, Zippel H, Bensen W, Roux C . Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001; 344(5):333-40. DOI: 10.1056/NEJM200102013440503. View

10.

Lindsay R, Silverman S, Cooper C, Hanley D, Barton I, Broy S . Risk of new vertebral fracture in the year following a fracture. JAMA. 2001; 285(3):320-3. DOI: 10.1001/jama.285.3.320. View

11.

Cranney A, Guyatt G, Krolicki N, Welch V, Griffith L, Adachi J . A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int. 2001; 12(2):140-51. DOI: 10.1007/s001980170147. View

12.

Storm T, Thamsborg G, Steiniche T, Genant H, Sorensen O . Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 1990; 322(18):1265-71. DOI: 10.1056/NEJM199005033221803. View

13.

Watts N, Harris S, Genant H, Wasnich R, Miller P, Jackson R . Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990; 323(2):73-9. DOI: 10.1056/NEJM199007123230201. View

14.

Chrischilles E, Butler C, Davis C, Wallace R . A model of lifetime osteoporosis impact. Arch Intern Med. 1991; 151(10):2026-32. View

15.

CHAPUY M, Arlot M, Duboeuf F, Brun J, Crouzet B, Arnaud S . Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med. 1992; 327(23):1637-42. DOI: 10.1056/NEJM199212033272305. View

16.

Liberman U, Weiss S, Broll J, Minne H, Quan H, Bell N . Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995; 333(22):1437-43. DOI: 10.1056/NEJM199511303332201. View

17.

. Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada. CMAJ. 1996; 155(8):1113-33. PMC: 1335371. View

18.

Black D, Cummings S, Karpf D, Cauley J, Thompson D, Nevitt M . Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348(9041):1535-41. DOI: 10.1016/s0140-6736(96)07088-2. View

19.

Cumming R, Nevitt M . Calcium for prevention of osteoporotic fractures in postmenopausal women. J Bone Miner Res. 1997; 12(9):1321-9. DOI: 10.1359/jbmr.1997.12.9.1321. View

20.

van Staa T, Abenhaim L, Cooper C . Use of cyclical etidronate and prevention of non-vertebral fractures. Br J Rheumatol. 1998; 37(1):87-94. DOI: 10.1093/rheumatology/37.1.87. View